Antimicrobial Agent Shortages: The New Norm for Infectious Diseases Physicians.
Antimicrobial Agent Shortages: The New Norm for Infectious Diseases Physicians.
复制标题
DOI：
10.1093/ofid/ofy068
复制
发表时间：
2018-04
影响因子：
4.2
通讯作者：
Members of the Emerging Infections Network
中科院分区：
文献类型：
--
作者：
Gundlapalli AV;Beekmann SE;Graham DR;Polgreen PM;Members of the Emerging Infections Network
2012年，美国食品和药物管理局（FDA）要求药品制造商提前通知即将发生的药品短缺。对传染病（ID）医生进行了一项调查，以确定这一要求的影响，并跟踪ID医生对抗菌药物短缺的先前看法。我们在2016年对新兴感染网络的ID医生成员进行了基于网络的调查。在1597名成员中的701名（44%）中，70%的人报告说，由于前2年的短缺，需要修改他们的抗菌药物选择。大多数人（73%）报告说，短缺影响了患者的护理或结果，因为使用了广谱（75%）、更昂贵（58%）、效果较差的二线药物（45%）或毒性更大（37%）。最常报告的供应短缺的抗菌药物是哌拉西林-他唑巴坦、氨苄西林-舒巴坦、美罗培南、头孢噻肟和头孢吡肟。受访者从医院通知、同事、药房订购短缺药物后的联系、FDA或其他网站了解到短缺情况。大多数（83%）受访机构的抗菌药物管理计划（ASP）已经制定了应对短缺的方法。尽管71%的受访者表示沟通已经足够，但大多数（87%）受访者认为自2012年FDA要求以来，有关短缺的沟通没有任何改善。ID医生报告的抗微生物剂短缺的持续存在令人不安，因为这导致需要使用更广谱或毒性更大的药物。ASP在帮助处理短缺、有效沟通渠道以及FDA沟通策略缺乏明显改善方面的突出作用值得进一步考虑。
In 2012, the US Food and Drug Administration (FDA) required drug manufacturers to give advance notice of impending drug shortages. A survey of infectious diseases (ID) physicians was undertaken to determine the impact of this requirement and to follow-up on prior perceptions of ID physicians on shortages of antimicrobial agents. We used a web-based survey of ID physician members of the Emerging Infections Network in 2016. Of the 701 of 1597 members (44%) who responded, 70% reported the need to modify their antimicrobial choice because of a shortage in the prior 2 years. A majority (73%) reported the shortages affected patient care or outcomes by the use of broader-spectrum (75%), more costly (58%), less effective second-line (45%), or more toxic agents (37%). The most commonly reported antimicrobials in short supply were piperacillin-tazobactam, ampicillin-sulbactam, meropenem, cefotaxime, and cefepime. Respondents learned of shortages from hospital notification, from a colleague, contact from pharmacy after ordering the agent in short supply, or FDA or other website. The antimicrobial stewardship programs (ASPs) of a majority (83%) of respondents’ institutions had developed approaches to deal with shortages. Although 71% indicated that communications were sufficient, most (87%) did not perceive any improvement in communications about shortages since the 2012 FDA requirement. The persistence of antimicrobial agent shortages reported by ID physicians is disturbing as is the resulting need to use broader-spectrum or more toxic agents. The prominent role of ASPs in helping to deal with shortages, effective communication channels, and the lack of perceived improvement in FDA’s communication strategy merit further consideration.
登录
查看更多内容
DOI：
10.1016/j.diagmicrobio.2012.11.020
发表时间：
2013-03-01
影响因子：
2.9
作者：
Gundlapalli, Adi V.;Beekmann, Susan E.;Polgreen, Philip M.
通讯作者：
Polgreen, Philip M.
影响因子：
5.4
作者：
McLaughlin, Milena M.;Skoglund, Erik;Scheetz, Marc H.
通讯作者：
Scheetz, Marc H.
影响因子：
11.8
作者：
Quadri, Farha;Mazer-Amirshahi, Maryann;May, Larissa
通讯作者：
May, Larissa
DOI：
10.1093/cid/cit932
发表时间：
2014-04
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Pillai SK;Beekmann SE;Santibanez S;Polgreen PM
通讯作者：
Polgreen PM
影响因子：
3.7
作者：
Scott JC;Shah N;Porco T;Flood J
通讯作者：
Flood J